Tag Archive for: HRRm
AMPLITUDE Trial Update: Niraparib Plus Abiraterone Shows Promise for HRR-Altered Metastatic Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxASCO GU 2025: Impact of Homologous Recombination Repair Alterations on Survival Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (BRCA, ATM, CDK12,…)
/0 Comments/in Observational, Retrospective studies/by MaxMatching-Adjusted Comparison of PARPi Therapies for mCRPC: Talazoparib + Enzalutamide Wins
/0 Comments/in Clinical Trial, Metastatic, Observational, Post-hoc, Retrospective studies/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide artificial intelligence ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy castration-resistant prostate cancer clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR HRRm immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology olaparib oncolytic virus personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 24/2025 June 15, 2025
- Cholesterol Identified as Key Shield in Heat-Resistant Cancer Cells June 13, 2025
- ATRN-119: A New Promising ATR Inhibitor for ATM Mutations (And Other HRR Mutations) June 13, 2025
- UPDATE: OncoACP3 Moving to Phase 1 Trial as Therapeutic Agent June 12, 2025